MDACC Study No:2011-0919 ( NCT No: NCT01585194)
Title:Phase II Study of Nivolumab in combination with Ipilimumab for Uveal Melanoma
Principal Investigator:Sapna P. Patel
Treatment Agent:Ipilimumab; Nivolumab
Study Status:Open
Study Description:The goal of this clinical research study is to learn if ipilimumab and
nivolumab can help to control uveal melanoma.

Ipilimumab is designed to increase the immune system's ability to fight cancer.

Nivolumab is an antibody (a protein that attacks foreign cells) that is
designed to allow the body’s immune system to work against tumor cells.
Hide details for General InformationGeneral Information

Disease Group:Melanoma
Phase of Study:Phase II
Treatment Agents:Ipilimumab
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Bristol Myers Squibb
University of Texas, MD Anderson Cancer Center
UTMDACC IRG - Clinical Research
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Sapna P. Patel
Dept:Melanoma Medical Oncology
For Clinical Trial Enrollment:713-792-2921
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults